Fenofibrate NIHFI - Pharmacology: Decreases plasma levels of triglycerides by decreasing synthesis. Also reduces plasma levels of VLDL cholesterol by reducing its release into the circulation and increasing catabolism. Reduces serum uric acid levels by increasing urinary excretion of uric acid.
Indication: Fenofibrate
Adjunctive therapy to diet to reduce elevated LDL cholesterol, total cholesterol, triglycerides and apolipoprotein B, and to increase HDL cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia (Fredrickson types IIa and IIb). Adjunctive therapy to diet for treatment of hypertriglyceridemia (Fredrickson types IV and V hyperlipidemia).
Fenofibric acid ( Trilipix )
Adjunct to diet in combination with an HMG-CoA reductase inhibitor to reduce triglycerides and increase HDL cholesterol in patients with mixed dyslipidemia and coronary heart disease or a coronary heart disease risk equivalent who are on optimal statin therapy to achieve LDL cholesterol goal; adjunctive therapy to diet to reduce triglycerides in patients with severe hypertriglyceridemia; adjunctive therapy to diet to reduce elevated LDL cholesterol, total cholesterol, triglycerides, and apolipoprotein B, and to increase HDL cholesterol in patients with primary hyperlipidemia or mixed dyslipidemia.
Unlabeled Uses
Hyperuricemia; hypertriglyceridemia associated with HIV lipodystrophy.
Used for: Controlling high cholesterol and triglyceride levels in the blood. It is used in combination with a diet that is low in cholesterol and saturated fat.
Fenofibrate NIHFI is a lipid-lowering agent. It works by lowering elevated blood triglyceride levels by making the liver produce fewer triglycerides and increasing the elimination of triglycerides from the blood stream.
Fenofibrate NIHFI is a lipid regulating agent indicated as adjunctive therapy to diet to reduce elevated LDL-C, Total-C,Triglycerides and Apo B, and to increase HDL-C in adult patients with primary hypercholesterolemia or mixed dyslipidemia (Fredrickson Types IIa and IIb). Fenofibrate NIHFI is also indicated as adjunctive therapy to diet for treatment of adult patients with hypertriglyceridemia (Fredrickson Types IV and V hyperlipidemia). Fenofibric acid, the active metabolite of Fenofibrate, produces reductions in total cholesterol, LDL cholesterol, apolipoprotein B, total triglycerides and triglyceride rich lipoprotein (VLDL) in treated patients. In addition, treatment with Fenofibrate NIHFI results in increases in high density lipoprotein (HDL) and apoproteins apoAI and apoAII.
Fenofibrate NIHFI helps lower your cholesterol and triglyceride (fat) levels. Excessive cholesterol and fat in your body can clog up your blood vessels. This can lead to many health problems such as strokes and heart disease, including heart attacks. This medicine is meant to be taken as part of a complete cholesterol management programme that should include exercise, a healthy diet and lifestyle.
Oral Hyperlipidaemias
Adult: Dose depends on the formulation used. For standard micronised formulations: Initially, 67 mg tid or 200 mg once daily, may reduce to 67 mg bid or increase to 67 mg 4 times daily. For non-micronised formulations: Initially, 200-300 mg daily in divided doses. Usual range: 200-400 mg daily. For formulations with improved bioavailability, doses between 40-160 mg daily may be used.
Child: 5 mg/kg daily. Renal impairment: Dose reduction is necessary.
Indications: Hyperlipidaemia s.
Oral Hyperlipidaemias
Adult: Dose depends on the formulation used. For standard micronised formulations: Initially, 67 mg tid or 200 mg once daily, may reduce to 67 mg bid or increase to 67 mg 4 times daily. For non-micronised formulations: Initially, 200-300 mg daily in divided doses. Usual range: 200-400 mg daily. For formulations with improved bioavailability, doses between 40-160 mg daily may be used.
Child: 5 mg/kg daily. Renal impairment: Dose reduction is necessary. Special Populations: Reduce dose in patients with mild to moderate renal impairment: CrCl 20 mL/min: 100 mg daily; CrCl 60 mL/min: 200 mg daily. |
brands or generic drugs
